Entry Into a Material Definitive Agreement. On July 7, 2026, Bone Biologics Corporation (the “Company”) priced a private offering with an investor pursuant to which the Company agreed to sell to the investor pre-funded warrants (the “Pre-Funded Warrants”) to purchase 2,112,677 shares of its common stock, par value $0.001 per share (the “Common Stock”), together with Series F warrants (the “Series F Warrants”) to purchase 2,112,677 shares of Common Stock and Series G warrants (the “Series G Wa…

Unregistered Sales of Equity Securities. To the extent required by

Other Events. On March 13, 2026, Bone Biologics Corporation (the “Company”) filed a prospectus supplement (the “Prospectus Supplement”) w ith the U.S. Securities and Exchange Commission (the “SEC”) in connection with the Company’s “at the market offering” program for the offer and sale of up to $1,064,000 shares of the Company’s common stock, par value $0.001 per share (the “Shares”), from time to time through H.C. Wainwright & Co., LLC (“Wainright”), as sales agent, pursuant to the Company’s…

Entry Into a Material Definitive Agreement. On June 27, 2025, Bone Biologics Corporation (the “Company”) priced a public offering (the “Offering”) of (i) 793,750 shares (the “Shares”) of its common stock, par value $0.001 per share (the “Common Stock”), together with Series D warrants (the “Series D Warrants”) to purchase 793,750 shares of Common Stock and Series E warrants (the “Series E Warrants,” together with the Series D Warrants, the “Warrants”) to purchase 793,750 shares of Common Stoc…

Other Events. On June 6, 2025, the Company issued a press release announcing the Reverse Stock Split. A copy of the press release is attached as Exhibit 99.1 to this report. Forward-Looking Statements Certain statements contained in this report, including, without limitation, statements regarding the timing, implementation, and success of the Reverse Stock Split, as well as statements containing the words “expect,” “will,” and words of similar import, constitute “forward-looking statements” w…

Material Modification to Rights of Security Holders. On June 5, 2025, Bone Biologics Corporation (the “Company”) filed a Certificate of Amendment to amend its Amended and Restated Certificate of Incorporation (the “Certificate of Amendment”), with the Secretary of State of the State of Delaware. The Certificate of Amendment effects a reverse stock split of the Company’s common stock, par value $0.001 per share (the “Common Stock”) at a ratio of 1-for-6 shares, effective as of 12:01 a.m. Easte…

The filing is about an equity plan amendment, not a management change.

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On April 7, 2025, Bone Biologics Corporation (the “Company”) received a letter from the Listing Qualifications Staff of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, based upon the closing bid price of the Company’s common stock for the last 30 consecutive business days, the Company no longer meets Nasdaq Listing Rule 5550(a)(2), which requires listed companies to maintain a minimum…

Other Events. On December 13, 2024, Bone Biologics Corporation (the “Company”) filed a prospectus supplement to update the maximum amount of shares the Company is eligible to sell under the At The Market Offering Agreement (the “Sales Agreement”) with H.C. Wainwright & Co., LLC, dated September 27, 2024 to $832,009. The Company previously sold approximately $846,288 of shares of Common Stock pursuant to the Sales Agreement pursuant to a prior prospectus supplement dated September 27, 2024. A…

Director — Phillip Meikle: Phillip Meikle was appointed to the Board of Directors.

director — Don Hankey: Mr. Hankey resigned as a director of the Company effective immediately.

Entry Into a Material Definitive Agreement. On September 27, 2024, Bone Biologics Corporation (the “Company”) entered into an At The Market Offering Agreement (the “Agreement”) with H.C. Wainwright & Co., LLC, as sales agent (“Wainwright”), to sell shares of its common stock, par value $0.001 per share (the “Shares”) from time to time, in an “at the market offering” program through Wainwright, with certain limitations on the amount of Shares that may be offered and sold thereunder. The sales,…

Entry into a Material Definitive Agreement. On August 1, 2024, Bone Biologics Corporation, a Delaware corporation (the “Company”), entered into inducement letter agreements (collectively, the “Inducement Letter Agreements”) with the holders (the “Holders”) of its existing warrants to purchase 781,251 shares of the Company’s common stock, $0.001 par value (the “Common Stock”), originally issued on March 6, 2024, with an exercise price of $2.43 per share, and which became exercisable immediatel…

Unregistered Sales of Equity Securities. To the extent required by

Amended and restated agreements for the CEO and CFO, including transaction bonuses.

Entry Into a Material Definitive Agreement. On March 4, 2024, Bone Biologics Corporation (the “Company”) priced a public offering (the “Offering”) of (i) 119,000 shares (the “Shares”) of its common stock, par value $0.001 per share (the “Common Stock”), together with warrants (the “Warrants”) to purchase 119,000 shares of Common Stock at a combined public offering price of $2.56 per Share and accompanying Warrant and (ii) pre-funded warrants (the “Pre-Funded Warrants”) to purchase 662,251 sha…

Other Events. On January 10, 2024, Bone Biologics Corporation (the “Company”) entered into a Settlement Agreement and Mutual General Release (the “Agreement”) with Drs. Bessie (Chia) Soo and Kang (Eric) Ting, on the one hand (the “plaintiffs”), and Stephen LaNeve on the other hand (together with the Company, the “defendants”), in settlement of the claims for breach of contract and tortious interference with contract against the defendants filed in the United States District Court for the Dist…

Director — Robert E. Gagnon: Appointment of Robert E. Gagnon to the Board of Directors, replacing Erick Lucera.

Director — Erick Lucera: Mr. Lucera resigned as a director, effective upon the appointment of a new director.

Other Events. On December 18, 2023, the Company issued a press release announcing the Reverse Stock Split. A copy of the press release is attached as Exhibit 99.1 to this report. Forward-Looking Statements Certain statements contained in this report, including, without limitation, statements regarding the timing, implementation, and success of the Reverse Stock Split, as well as statements containing the words “expect,” “will,” and words of similar import, constitute “forward-looking statemen…

Material Modification to Rights of Security Holders. On December 14, 2023, Bone Biologics Corporation (the “Company”) filed a Certificate of Amendment to amend its Amended and Restated Certificate of Incorporation (the “Certificate of Amendment”) with the Secretary of State of the State of Delaware. The Certificate of Amendment effects a reverse stock split of the Company’s common stock, par value $0.001 per share (the “Common Stock”) at a ratio of 1-for-8 shares, effective as of 12:01 a.m. E…

Other Events. As previously disclosed, on September 27, 2023, the Company received a written notice from the Nasdaq Stock Market (“Nasdaq”) notifying the Company that it was not in compliance with the $1.00 per share minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2) and that Nasdaq’s staff had determined to delist the Company’s securities (the “Staff Determination”). On November 30, 2023, the Company presented its plan for regaining and sustaining compliance with all a…

Unregistered Sales of Equity Securities. The information under

Entry Into a Material Definitive Agreement. On November 16, 2023, Bone Biologics Corporation (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with certain institutional investors (the “Purchasers”), pursuant to which the Company agreed to sell and issue, in a registered direct offering (the “Registered Direct Offering”), 1,139,063 shares (the “Shares”) of the Company’s common stock, $0.001 par value per share (the “Common Stock”), at an offering price of…

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On September 27, 2023, Bone Biologics Corporation (the “Company”) received a written notice (the “Notice”) from the staff of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that it failed to comply with the $1.00 per share minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2). As a result of the imposition of a mandatory Panel Monitor, as previously disclosed o…